[Federal Register Volume 88, Number 125 (Friday, June 30, 2023)]
[Notices]
[Pages 42374-42375]
[FR Doc No: 2023-13936]

-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket Nos. FDA-2013-N-1427; FDA-2022-N-0863; FDA-2023-N-0187; FDA-
2013-N-1393; FDA-2022-D-0814; FDA-2013-N-0796; FDA-2016-N-0736; and
FDA-2019-N-3065]

Agency Information Collection Activities; Announcement of Office
of Management and Budget Approvals

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA) is publishing a list of
information collections that have been approved by the Office of
Management and Budget (OMB) under the Paperwork Reduction Act of 1995.

FOR FURTHER INFORMATION CONTACT: JonnaLynn Capezzuto, Office of
Operations, Food and Drug Administration, Three White Flint North, 10A-
12M, 11601 Landsdown St., North Bethesda, MD 20852,<PHONE_NUMBER>,
[email protected].

SUPPLEMENTARY INFORMATION: The following is a list of FDA information
collections recently approved by OMB under section 3507 of the
Paperwork Reduction Act of 1995 (44 U.S.C. 3507). The OMB control
number and expiration date of OMB approval for each information
collection are shown in table 1. Copies of the supporting statements
for the information collections are available on the internet at
https://www.reginfo.gov/public/do/PRAMain. An Agency may not conduct or
sponsor, and a person is not required to respond to, a collection of
information unless it displays a currently valid OMB control number.

        Table 1--List of Information Collections Approved By OMB
------------------------------------------------------------------------
                                            OMB control    Date approval
           Title of collection                  No.           expires
------------------------------------------------------------------------
Hazard Analysis and Critical Control           0910-0466       4/30/2026
 Point (HACCP) Procedures for the Safe
 and Sanitary Processing and Importing
 of Juice...............................
Monthly Monitoring Study................       0910-0914       4/30/2026
Premarket Approval of Medical Devices...       0910-0231       5/31/2026
Patent Term Restoration, Due Diligence         0910-0233       5/31/2026
 Petitions, Filing, Format, and Content
 of Petitions...........................
Infant Formula Requirements.............       0910-0256       5/31/2026
Testing Communications on Medical              0910-0678       5/31/2026
 Devices and Radiation-Emitting Products
Tracking Network for PETNet,                   0910-0680       5/31/2026
 LivestockNet, and SampleNet............
Required Warnings for Cigarette Packages       0910-0877       5/31/2026
 and Advertisements.....................
------------------------------------------------------------------------

    Dated: June 26, 2023.
Lauren K. Roth,
Associate Commissioner for Policy.
[FR Doc. 2023-13936 Filed 6-29-23; 8:45 am]
BILLING CODE 4164-01-P


[Federal Register Volume 77, Number 207 (Thursday, October 25, 2012)]
[Notices]
[Pages 65198-65199]
[FR Doc No: 2012-26256]

-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2012-N-0007]

Generic Drug User Fee--Abbreviated New Drug Application, Prior
Approval Supplement, and Drug Master File Fee Rates for Fiscal Year
2013

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA) is announcing the rate
for the Abbreviated New Drug Application (ANDA), Prior Approval
Supplement (PAS), and Drug Master File (DMF) fees related to the
Generic Drug User Fee Program for fiscal year (FY) 2013. The Federal
Food, Drug, and Cosmetic Act (the FD&C Act), as amended by the Generic
Drug User Fee Amendments of 2012 (GDUFA), as further amended by the FDA
User Fee Correction Act of 2012, authorizes FDA to assess and collect
user fees for certain applications and supplements for human generic
drug products, on applications in the backlog as of October 1, 2012, on
finished dosage form (FDF) and active pharmaceutical ingredient (API)
facilities, and on type II active pharmaceutical ingredient DMFs to be
made available for reference. GDUFA directs FDA to establish each year
the Generic Drug User Fee rates for the upcoming year. In the first
year of GDUFA (FY 2013), some rates will be published in separate
Federal Register notices because of the timing specified in the
statute. Each year thereafter the GDUFA fee rates will be published 60
days before the start of the FY. This document establishes FY 2013
rates for an ANDA ($51,520), PAS ($25,760), and DMF ($21,340). These
fees are effective on October 1, 2012, and will remain in effect
through September 30, 2013.

FOR FURTHER INFORMATION CONTACT: David Miller, Office of Financial
Management (HFA-100), Food and Drug Administration, 1350 Piccard Dr.,
PI50, rm. 210J, Rockville, MD 20850,<PHONE_NUMBER>.

SUPPLEMENTARY INFORMATION:

I. Background

    Sections 744A and 744B of the FD&C Act (21 U.S.C. 379j-41 and 379j-
42), as added by GDUFA (Title III of the Food and Drug Administration
Safety and Innovation Act (Pub. L. 112-144), which was signed by the
President on July 9, 2012), as further amended by the FDA User Fee
Correction Act of 2012 (Pub. L. 112-193) (signed by the President on
October 5, 2012), establish fees associated with human generic drug
products. Fees are assessed on the following: (1) Certain applications
in the backlog as of October 1, 2012; (2) certain types of applications
and supplements for human generic drug products; (3) certain facilities
where APIs and FDFs are produced; and (4) certain DMFs associated with
human generic drug products (section 744B(a) of the FD&C Act). This
notice will focus on the ANDA, PAS, and DMF fees.

II. Fee Revenue Amount for FY 2013

    The total fee revenue amount for FY 2013 is $299,000,000, as set in
the statute. GDUFA directs FDA to use the yearly revenue amount as a
starting point to set the fee rates for each fee type. GDUFA states
that the backlog fee will make up $50,000,000 of the total revenue
collected for FY 2013. Therefore, the rest of the fees will make up a
percentage of the remaining $249,000,000 of the total revenue. For more
information about GDUFA, please refer to the FDA Web site (http://www.fda.gov/gdufa). The ANDA, PAS, and DMF fee calculations for FY 2013
are described in this document.

III. ANDA and PAS Fees

    Under GDUFA, the ANDA and PAS fees are owed by each applicant that
submits, on or after October 1, 2012, an ANDA or a PAS. These fees are
due on the date of submission of the ANDA or PAS or 30 days after the
publication date of this notice, whichever is later. Section
744B(b)(2)(B) specifies that the

ANDA and PAS fees will make up 24 percent of the $249,000,000, which is
$59,760,000.
    In order to calculate the ANDA fee, FDA needed to estimate the
number of full application equivalents (FAEs) that will be submitted in
FY 2013. Over the past 4 years, the average number of ANDAs that would
have been subject to the fee was approximately 850. Because the number
of prior approval supplements submitted in FY 2012 is significantly
lower than the number submitted in the 2 previous years, FDA has
utilized available data concerning FY 2012 to estimate the number of
such supplements for FY 2013. The estimated number of PASs to be
received in FY 2013 is 576 based on an annualized estimate of the
number of receipts for FY 2012.
    In estimating the number of fee-paying FAEs, applications count as
one FAE and supplements count as one-half an FAE, since the fee for a
PAS is one-half of the fee for an ANDA. GDUFA requires that 75 percent
of the fees paid for an ANDA or PAS be refunded if its receipt is
refused due to issues other than failure to pay fees (section
744B(a)(3)(D) of the FD&C Act). Therefore, an application or supplement
that is considered not to have been received by the Secretary due to
reasons other than failure to pay fees counts as one-fourth of an FAE
if the applicant initially paid a full application fee, or one-eighth
of an FAE if the applicant initially paid the supplement fee (one-half
of the full application fee amount).
    Taking into account estimates of the number of ANDAs and PASs that
are likely to be refused due to issues other than failure to pay fees,
and the number that are likely to be resubmitted in the same fiscal
year, FDA estimates that the total number of fee-paying FAEs that will
be received in FY 2013 is 1,160.
    The FY 2013 application fee is estimated by dividing the number of
full application equivalents that will pay the fee in FY 2013 (1,160)
into the fee revenue amount to be derived from application fees in FY
2013 ($59,760,000). The result, rounded to the nearest $10, is a fee of
$51,520 per ANDA. Section 744B(b)(2)(B) of the FD&C Act states that the
PAS fee is equal to half the ANDA fee; therefore the PAS fee is
$25,760. We note that the statute provides that those ANDAs that
include information about the production of active pharmaceutical
ingredients other than by reference to a DMF will pay an additional fee
that is based on the number of such active pharmaceutical ingredients
and the number of facilities proposed to produce those ingredients.
(See section 744B(a)(3)(F) of the FD&C Act.) FDA considers this
additional fee to be unlikely to be assessed often; therefore, FDA has
not included projections concerning the amount of this fee in
calculating the fees for ANDAs and PASs.

IV. DMF Fee

    Under GDUFA, the DMF fee is owed by each person that owns a type II
active pharmaceutical ingredient drug master file that is referenced,
on or after October 1, 2012, in a generic drug submission by an initial
letter of authorization. This is a one-time fee for each individual
DMF. This fee is due no later than the date on which the first generic
drug submission is submitted that references the associated DMF, or 30
days after publication of this notice, whichever is later. (Under
section 744B(a)(2)(D)(iii) of the FD&C Act, if the DMF successfully
undergoes an initial completeness assessment and the fee is paid, the
DMF will be placed on a publicly available list documenting DMFs
available for reference. Thus some DMFs holders may choose to pay the
fee prior to the date that it would otherwise be due in order to have
the DMF placed on that list.) Section 744B(b)(2)(A) of the FD&C Act
specifies that the DMF fee will make up 6 percent of the remaining
$249,000,000, which is $14,940,000.
    In order to calculate the DMF fee, FDA must estimate the number of
DMFs that will be referenced by an initial letter of reference in FY
2013. This number will include DMFs that have been referred to in ANDAs
prior to FY 2013, but that are first referred to in an initial letter
of reference in an ANDA during that year. Based on the numbers of DMFs
referenced by ANDAs and PASs in 2011, the last full calendar year for
which DMF information is available, FDA is estimating that 700 DMFs
will be referenced by an initial letter of reference in FY 2013.
Dividing the DMF revenue of $14,940,000 by the estimated number of
first-referenced DMFs (700), and rounding to the nearest $10, yields a
DMF fee of $21,340 for FY 2013.

V. Fee Payment Options and Procedures

    To pay the ANDA, PAS, or DMF fee, you must complete a generic drug
user fee cover sheet, available at http://www.fda.gov/gdufa starting in
October 2012, and generate a user fee identification (ID) number.
Payment must be made in U.S. currency drawn on a U.S. bank by
electronic check, check, bank draft, U.S. postal money order, or wire
transfer.
    FDA has partnered with the U.S. Department of the Treasury to
utilize Pay.gov, a Web-based payment application, for online electronic
payment. The Pay.gov feature is available on the FDA Web site after
completing the generic drug user fee cover sheet and generating the
user fee ID number.
    Please include the user fee ID number on your check, bank draft, or
postal money order and make payable to the order of the Food and Drug
Administration. Your payment can be mailed to: Food and Drug
Administration, P.O. Box 979108, St. Louis, MO 63197-9000. If checks
are to be sent by a courier that requests a street address, the courier
can deliver the checks to: U.S. Bank, Attention: Government Lockbox
979108, 1005 Convention Plaza, St. Louis, MO 63101. (Note: This U.S.
Bank address is for courier delivery only.) Please make sure that the
FDA post office box number (P.O. Box 979108) is written on the check,
bank draft, or postal money order.
    If paying by wire transfer, please reference your unique user fee
ID number when completing your transfer. The originating financial
institution may charge a wire transfer fee. Please ask your financial
institution about the fee and include it with your payment to ensure
that your fee is fully paid. The account information is as follows: New
York Federal Reserve Bank, U.S. Department of Treasury, TREAS NYC, 33
Liberty St., New York, NY 10045, account number: 75060099, routing
number: 021030004, SWIFT: FRNYUS33, Beneficiary: FDA, 1350 Piccard Dr.,
Rockville, MD 20850. The tax identification number of the Food and Drug
Administration is 53-0196965.

    Dated: October 16, 2012.
Leslie Kux,
Assistant Commissioner for Policy.
[FR Doc. 2012-26256 Filed 10-24-12; 8:45 am]
BILLING CODE 4160-01-P